Aptose Biosciences Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Changes in Shareholders' Equity

Consolidated Statements of Changes in Shareholders' Equity - USD ($) $ in Thousands	Public Offering [Member] Common Stock [Member]	Public Offering [Member]	December 2019 Public Offering [Member] Common Stock [Member]	December 2019 Public Offering [Member]	June 2019 Public Offering [Member] Common Stock [Member]	June 2019 Public Offering [Member]	The 2019 Share Purchase Agreement [Member] Common Stock [Member]	The 2019 Share Purchase Agreement [Member]	The 2018 ATM Offering [Member] Common Stock [Member]	The 2018 ATM Offering [Member]	The 2018 Purchase Agreement [Member] Common Stock [Member]	The 2018 Purchase Agreement [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2018													38,162,000
Balance at Dec. 31, 2018													$ 261,072	$ 32,963	$ (4,316)	$ (275,638)	$ 14,081
Common shares issued (in shares)			18,544,000		11,500,000		1,971,000		77,000		5,502,000
Common shares issued			$ 68,588	$ 68,588	$ 19,594	$ 19,594	$ 4,730	$ 4,730	$ 178	$ 178	$ 10,000	$ 10,000
Common shares issued on redemption of restricted share units (in shares)													40,000
Common shares issued on redemption of restricted share units													$ 80	(80)
Common shares issued upon exercise of stock options (in shares)													312,000				312,000
Common shares issued upon exercise of stock options													$ 1,248	(530)			$ 718
Stock-based compensation														2,296			2,296
Other comprehensive gain															18		18
Net loss																(26,277)	(26,277)
Balance (in shares) at Dec. 31, 2019													76,108,000
Balance at Dec. 31, 2019													$ 365,490	34,649	(4,298)	(301,915)	93,926
Common shares issued (in shares)	11,854,000											5,502,433
Common shares issued	$ 58,234	$ 58,234
Common shares issued on redemption of restricted share units (in shares)													685,000
Common shares issued on redemption of restricted share units													$ 4,801	(4,801)
Common shares issued upon exercise of stock options (in shares)													235,000				235,000
Common shares issued upon exercise of stock options													$ 998	(425)			$ 573
Stock-based compensation														21,438			21,438
Other comprehensive gain															(18)		(18)
Net loss																(55,238)	(55,238)
Balance (in shares) at Dec. 31, 2020													88,882,000
Balance at Dec. 31, 2020													$ 429,523	$ 50,861	$ (4,316)	$ (357,153)	$ 118,915